Taiwan Cancer Moonshot Project

Recruiting

• Conditions: Malignant Neoplasm of Body of Stomach in Situ

• Registration Number: NCT05248763
• Lead Sponsor: Academia Sinica, Taiwan

Brief Summary

The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.

Detailed Description

Multiomic integrative analysis is an effective strategy to facilitate the investigation of molecular mechanism, cause, and early intervention of specific diseases. Gastric cancer is specifically chosen for our research target to decrease its incidence and improve survival. To increase precision diagnosis, prognosis and precision therapy, patients from Taiwan are selected as cohort subjects. The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform. Genome, transcriptome, genomic methylation, proteomics, and post-translational modification will be used to construct a map for determine the in-depth carcinogenesis of gastric cancer and strategies for cancer early diagnosis, prevention, and targeted treatments.

Study Timeline

• Study First Submitted: 2022-01-24
• Study First Submitted QC: 2022-02-08
• Study Start: 2022-02-21
• Study First Posted: 2022-02-21
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-18
• Last Update Posted: 2022-07-20
• Primary Completion: 2026-12-31
• Study Completion: 2035-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 4190

Inclusion Criteria

• lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer

Exclusion Criteria

• other cancer types

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data	Through study completion, an average of 2 to 3 year	Analyze collected clinical samples by using integrated proteomics and genetics platform (genome, transcriptome, genomic methylation, proteomics, and post-translational modification)

Secondary Outcome Measures

Name	Time	Method
Differential expressed genes and proteins in tumor	Through study completion, an average of 4 year	The relative difference, or fold change of expressed genes and proteins (tumors vs adjacent normal tissue)

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan